Pratik Shah - 02 Jan 2026 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Reporting relationship: President, CEO and Chairperson, Director
Issuer ticker: DSGN
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:08:50 UTC
Prior SEC filing: 11 Dec 2025
Next SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mustapha Parekh, Attorney-in-Fact

Key filing fact

Pratik Shah filed Form 4 for Design Therapeutics, Inc. (DSGN) on 05 Jan 2026.

Key facts

This page summarizes Pratik Shah's Form 4 filing for Design Therapeutics, Inc. (DSGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 16:08.

Change

Previous filing in this sequence was filed on 11 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001580787 Primary reporting owner

Shah Pratik

Relationship: President, CEO and Chairperson, Director
Address: C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD
Signature: /s/ Mustapha Parekh, Attorney-in-Fact
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DSGN transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +750,000
Change %
Price: $0.000000
Shares after: 750,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 750,000
Exercise price: $9.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.